Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti–Programmed Death-Ligand 1 and Anti–Vascular Endothelial Growth Factor-A Antibodies. Here, VEGFA is linked to hepatocellular carcinoma.